EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Continuous‐Time Markov Population PK/PD Modeling of Longitudinal EASI Categorical Score in Atopic Dermatitis Treated With Rocatinlimab, an Anti‐OX40 Monoclonal Antibody

Hiroki Okada iD, Sam Liao, Lisa Khouri, Lori Liao, Matthew W Hruska iD, Yoshinori Nagata, Maki Hasegawa, Andrew Gewitz iD, Douglas Marsteller iD

CPT: Pharmacometrics & Systems Pharmacology · 2025

DOI: 10.1002/psp4.70069 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Hiroki Okada und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Kyowa Kirin Co., Ltd, Tokyo, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Models, Biological, Antibodies, Monoclonal, Humanized, Receptors, OX40. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rocatinlimab (AMG 451/KHK4083) is a potential T‐cell rebalancing therapy that inhibits and reduces the number of pathogenic T cells by targeting the OX40 receptor; it is associated with a progressive and sustained response for patients with moderate‐to‐severe atopic dermatitis (AD). This population pharmacokinetic‐pharmacodynamic (PPK‐PD) analysis of rocatinlimab analyzed the longitudinal relationship between drug exposure and response using a four‐state continuous‐time Markov model. The model was developed using a two‐compartment PPK model for exposure based on five clinical studies and the categorical scores of Eczema Area and Severity Index (EASI) response from two clinical studies in AD (NCT03096223/NCT03703102). EASI categorical score was classified by percentage reduction from baseline (EASI 0 : < 50%; EASI 50 : ≥ 50% to < 75%; EASI 75 : ≥ 75% to < 90%; EASI 90 : ≥ 90%) following rocatinlimab exposure. Overall, 413 patients/healthy subjects were included in the full PPK dataset. The observed serum concentration‐time data following rocatinlimab exposure was well described using the two‐compartment PPK model. For PPK‐PD analysis, EC 50 and E max estimates were 24.0 μg/mL (% relative standard error [RSE]: 32.4) and 1.26 (%RSE: 25.4), respectively, with dropout probability for EASI 0 (0.0291) greater than for other EASI categories. Race was identified as a covariate but was not clinically meaningful. The PPK‐PD model adequately described the time course and drug‐related change in EASI score and was used to simulate various dosage regimens to predict the time course of EASI response. The identified parameters and drug‐exposure relationship were considered to potentially support dose revisions and optimization for phase 3 trials in patients with moderate‐to‐severe AD that are utilizing a subcutaneous regimen with dosing every 4 weeks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicModels, BiologicalAntibodies, Monoclonal, HumanizedReceptors, OX40HumansMarkov ChainsMaleAdultFemaleMiddle AgedSeverity of Illness IndexYoung AdultAdolescent

Stichwörter der Autor:innen

doseefficacyexposure‐responsemodelingmodel‐informed drug developmentoptimizationpharmacometricspopulation pharmacokinetic‐pharmacodynamic

Substanzen

Antibodies, Monoclonal, HumanizedReceptors, OX40

Autor:innen und Institutionen

  • Clinical Pharmacology, Kyowa Kirin Co., Ltd, Tokyo, Japan.
  • PharMax Research Inc., Irvine, California, USA.
  • Clinical Pharmacology, Kyowa Kirin, Inc., Princeton, New Jersey, USA.

ORCID-Profile: Hiroki Okada, Matthew W Hruska, Andrew Gewitz, Douglas Marsteller

Zitieren

APA

Okada, H., Liao, S., Khouri, L., Liao, L., Hruska, M. W., Nagata, Y., Hasegawa, M., Gewitz, A., & Marsteller, D. (2025). Continuous‐Time Markov Population PK/PD Modeling of Longitudinal EASI Categorical Score in Atopic Dermatitis Treated With Rocatinlimab, an Anti‐OX40 Monoclonal Antibody. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70069

Vancouver

Okada H, Liao S, Khouri L, Liao L, Hruska MW, Nagata Y, et al. Continuous‐Time Markov Population PK/PD Modeling of Longitudinal EASI Categorical Score in Atopic Dermatitis Treated With Rocatinlimab, an Anti‐OX40 Monoclonal Antibody. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.70069

BibTeX
@article{Okada2025,
  author = {Okada, Hiroki and Liao, Sam and Khouri, Lisa and Liao, Lori and Hruska, Matthew W and Nagata, Yoshinori and Hasegawa, Maki and Gewitz, Andrew and Marsteller, Douglas},
  title = {Continuous‐Time Markov Population PK/PD Modeling of Longitudinal EASI Categorical Score in Atopic Dermatitis Treated With Rocatinlimab, an Anti‐OX40 Monoclonal Antibody},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2025},
  doi = {10.1002/psp4.70069}
}
Kostenlos starten →